Constitutive formation of an RXFP1-signalosome: A novel paradigm in GPCR function and regulation

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1644-1658

  Halls, Michelle L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cAMP; concentration biased; constitutive activity; GPCR; relaxin; signalling; signalosome

Indexed keywords

BETA ARRESTIN; CYCLIC AMP; DOPAMINE 4 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; RELAXIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; SCAFFOLD PROTEIN; SIGNALOSOME; THYROTROPIN; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIFIBROTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; LIGAND BINDING; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84857482783     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01470.x     Document Type: Review

References (151)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Alleva DG, Kaser SB, Monroy MA, Fenton MJ, Beller DI, (1997). IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J Immunol 159: 2941-2951.
3. Anand-Ivell R, Heng K, Bartsch O, Ivell R, (2007). Relaxin signalling in THP-1 cells uses a novel phosphotyrosine-dependent pathway. Mol Cell Endocrinol 272: 1-13.
4. Baillie GS, Scott JD, Houslay MD, (2005). Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579: 3264-3270.
5. Bartsch O, Bartlick B, Ivell R, (2001). Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity. Mol Hum Reprod 7: 799-809.
6. Bartsch O, Bartlick B, Ivell R, (2004). Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 89: 324-334.
7. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ, (2006). International union of pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 58: 7-31.
8. Bauman AL, Soughayer J, Nguyen BT, Willoughby D, Carnegie GK, Wong W, et al,. (2006). Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. Mol Cell 23: 925-931.
9. Bennett RG, Kharbanda KK, Tuma DJ, (2003). Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem Pharmacol 66: 867-874.
10. Bigazzi M, Brandi ML, Bani G, Sacchi TB, (1992). Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration. Cancer 70: 639-643.
11. Binder C, Hagemann T, Husen B, Schultz M, Einspanier A, (2002). Relaxin enhances in vitro invasiveness of breast cancer cell lines by upregulation of matrix metalloproteinases. Mol Hum Reprod 8: 789-796.
12. Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G, et al,. (2004). Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat 87: 157-166.
13. Böhm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, et al,. (1994). Radioimmunochemical quantification of Giα in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 26: 133-149.
14. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, et al,. (2003). The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with β-arrestins. J Biol Chem 278: 49230-49238.
15. Bond CP, Parry LJ, Samuel CS, Gehring HM, Lederman FL, Rogers PAW, et al,. (2004). Increased expression of the relaxin receptor (LGR7) in the human endometrium during the secretory phase of the menstrual cycle. J Clin Endocrinol Metab 89: 3477-3485.
16. Bouschet T, Martin S, Kanamarlapudi V, Mundell S, Henley JM, (2007). The calcium-sensing receptor changes cell shape via a β-arrestin-1 ARNO ARF6 ELMO protein network. J Cell Sci 120: 2489-2497.
17. Brown EM, Brauner-Osborne H, Bikle D, Conigrave A, Shoback D, (2010). Calcium-sensing receptors. Last modified on 2010-06-29. Accessed on 2011-01-10. IUPHAR Database (IUPHAR-DB) http://www.iuphar-db.org/DATABASE/FamilyMenuForward? familyId=12.
18. Callander GE, Thomas WG, Bathgate RA, (2009). Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of β-arrestin recruitment. Am J Physiol Cell Physiol 296: C1058-C1066.
19. Chen GA, Huang JR, Tseng L, (1988). The effect of relaxin on cyclic adenosine 3â€,5â€-monophosphate concentrations in human endometrial glandular epithelial cells. Biol Reprod 39: 519-525.
20. Conrad KP, Novak J, (2004). Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol 287: R250-R261.
21. Cronin MJ, Malaska T, Bakhit C, (1987). Human relaxin increases cyclic AMP levels in cultured anterior pituitary cells. Biochem Biophys Res Commun 148: 1246-1251.
22. DeFea KA, (2008). Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 153 (Suppl. 1): S298-S309.
23. DeFea KA, (2011). Beta-arrestins as regulators of signal termination and transduction: hoe do they determine what to scaffold? Cell Signal 23: 621-629.
24. Defer N, Best-Belpomme M, Hanoune J, (2000). Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol 279: F400-F416.
25. Dessauer CW, (2009). Adenylyl cyclase-a-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 76: 935-941.
26. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK, (2007). β-arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
27. Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster FP, Baumann G, et al,. (2001). The pregnancy hormone relaxin is a player in human heart failure. FASEB J 15: 2187-2195.
28. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K, (2003). Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist. Attenutation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-ΰB. Circ Res 92: 32-40.
29. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al,. (2009a). Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 15: 182-190.
30. Dschietzig T, Bartsch C, Baumann G, Stangl K, (2009b). RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul Pept 154: 77-84.
31. Dschietzig T, Bartsch C, Wessler S, Baumann G, Stangl K, (2009c). Autoregulation of human relaxin-2 gene expression critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter. Regul Pept 155: 163-173.
32. i-phosphoinositide-3 kinase signalling. J Card Fail 17: 158-166.
33. Efendiev R, Samelson BK, Nguyen BT, Phatarpekar PV, Baameur F, Scott JD, et al,. (2010). AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and scaffolds AC5 and -6 to alpha-amino-3-hydroxyl-5-methyl-4-isoxazole- propionate (AMPA) receptors. J Biol Chem 285: 14450-14458.
34. Ehnert C, Tegeder I, Pierre S, Birod K, Nguyen HV, Schmidtko A, et al,. (2004). Protein associated with Myc (PAM) is involved in spinal nociceptive processing. J Neurochem 88: 948-957.
35. Einspanier A, Nubbemeyer R, Schlote S, Schumacher M, Ivell R, Fuhrmann K, et al,. (1999). Relaxin in the marmoset monkey: secretion pattern in the ovarian cycle and early pregnancy. Biol Reprod 61: 512-520.
36. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, et al,. (1992). Increased messenger RNA level of the inhibitory G protein α subunit Gαi2 in human end-stage heart failure. Circ Res 70: 688-696.
37. Fei DT, Gross MC, Lofgren JL, Mora-Worms M, Chen AB, (1990). Cyclic AMP response to recombinant human relaxin by cultured human endometrial cells-a specific and high throughput in vitro bioassay. Biochem Biophys Res Commun 170: 214-222.
38. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, et al,. (2007). Relaxin promotes prostate cancer progression. Clin Cancer Res 13: 1695-1702.
39. Fisher C, MacLean M, Morecroft I, Seed A, Johnston F, Hillier C, et al,. (2002). Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 106: 292-295.
40. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, et al,. (2001). Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59: 876-882.
41. Gellersen B, Brosens J, (2003). Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol 178: 357-372.
42. Halls ML, Cooper DM, (2010). Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex. EMBO J 29: 2772-2787.
43. 2+-signaling pathways of adenylyl cyclases. Cold Spring Harb Perspect Biol 3: a004143.
44. Halls ML, Bond CP, Sudo S, Kumagai J, Ferraro T, Layfield S, et al,. (2005). Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 313: 677-687.
45. Halls ML, Bathgate RAD, Summers RJ, (2006). Relaxin family peptide receptors, RXFP1 and RXFP2, modulate cAMP signalling by distinct mechanisms. Mol Pharmacol 70: 214-226.
46. Halls ML, Bathgate RAD, Summers RJ, (2007). Comparison of signalling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes. J Pharmacol Exp Ther 320: 281-290.
47. Halls ML, van der Westhuizen ET, Wade JD, Evans BA, Bathgate RA, Summers RJ, (2009a). Relaxin family peptide receptor (RXFP1) coupling to Gαi3 involves the C-terminal Arg752 and localization within membrane raft microdomains. Mol Pharmacol 75: 415-428.
48. Halls ML, Hewitson TD, Moore XL, Du XJ, Bathgate RA, Summers RJ, (2009b). Relaxin activates multiple cAMP signaling pathway profiles in different target cells. Ann N Y Acad Sci 1160: 108-111.
49. Hayes ES, Curnow EC, Trounson AO, Danielson LA, Unemori EN, (2004). Implantation and pregnancy following in vitro fertilization and the effect of recombinant human relaxin administration in Macaca fascicularis. Biol Reprod 71: 1591-1597.
50. Heeg MHJ, Koziolek MJ, Vasko R, Schaefer L, Sharma K, Muller GA, et al,. (2005). The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68: 96-109.
51. Heng K, Ivell R, Wagaarachchi P, Anand-Ivell R, (2008). Relaxin signalling in primary cultures of human myometrial cells. Mol Hum Reprod 14: 603-611.
52. Hisaw FL, (1926). Experimental relaxation of the pubic ligament of the guinea-pig. Proc Soc Exp Biol Med 23: 661-663.
53. Ho TY, Yan W, Bagnell CA, (2007). Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-ΰB pathway in human THP-1 cells. J Leukoc Biol 81: 1303-1310.
54. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen H-J, Silvertown JD, et al,. (2006). Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 169: 617-632.
55. Hopkins EJ, Layfield S, Ferraro T, Bathgate RAD, Gooley PR, (2007). The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation. J Biol Chem 282: 4172-4184.
56. Houslay MD, (2010). Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100.
57. Houslay MD, Baillie GS, (2005). β-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of β2-adrenoceptor signalling to activation of ERK. Biochem Soc Trans 33: 1333-1336.
58. Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, van der Spek PJ, et al,. (2000). The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 14: 1257-1271.
59. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al,. (2002). Activation of orphan receptors by the hormone relaxin. Science 295: 671-674.
60. Huang JR, Tseng L, Bischof P, Janne OA, (1987). Regulation of prolactin production by progestin, estrogen, and relaxin in human endometrial stromal cells. Endocrinology 121: 2011-2017.
61. Kakouris H, Eddie LW, Summers RJ, (1992). Cardiac effects of relaxin in rats. Lancet 339: 1076-1078.
62. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, et al,. (2006). The role of relaxin in endometrial cancer. Cancer Biol Ther 5: 71-77.
63. Kelly E, Bailey CP, Henderson G, (2008). Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153 (Suppl. 1): S379-S388.
64. Kenakin T, (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
65. Kern A, Bryant-Greenwood GD, (2009). Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cells. Endocrinology 150: 2419-2428.
66. Kern A, Agoulnik AI, Bryant-Greenwood GD, (2007). The low-density lipoprotein class a module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane. Endocrinology 148: 1181-1194.
67. Kern A, Hubbard D, Amano A, Bryant-Greenwood GD, (2008). Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing g protein-coupled receptor 7) splice variants from human fetal membranes. Endocrinology 149: 1277-1294.
68. Kompa AR, Samuel CS, Summers RJ, (2002). Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin. Br J Pharmacol 137: 710-718.
69. Kosugi S, Mori T, Shenker A, (1996). The role of Asp578 in maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor. J Biol Chem 271: 31813-31817.
70. Kosugi S, Mori T, Shenker A, (1998). An anionic residue at position 564 is important for maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor. Mol Pharmacol 53: 894-901.
71. Kumagai J, Hsu SY, Matsumi H, Roh J-S, Fu P, Wade JD, et al,. (2002). INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent. J Biol Chem 277: 31283-31286.
72. Kuznetsova L, Plesneva S, Derjabina N, Omeljaniuk E, Pertseva M, (1999). On the mechanism of relaxin action: the involvement of adenylyl cyclase signalling system. Regul Pept 80: 33-39.
73. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, et al,. (1995). Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci USA 92: 1906-1910.
74. Laue L, Wu SM, Kudo M, Hsueh AJ, Cutler GB Jr, Jelly DH, et al,. (1996). Heterogeneity of activating mutations of the human luteinizing hormone receptor in male-limited precocious puberty. Biochem Mol Med 58: 192-198.
75. Lewis M, Deshpande U, Gizman L, Grove BH, Huang X, Erikson ME, et al,. (2001). Systemic relaxin administration stimulates angiogenic cytokine expression and vessel formation in a rat myocardial infarct model. In:, Tregear GW, Ivell R, Bathgate RA, Wade JD, (eds). Relaxin 2000, Proceedings of the Third Internation Conference on Relaxin and Related Peptides. Kluwer Academic Publishers: Broome, Australia, pp. 159-168.
76. Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, et al,. (2003). Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278: 50754-50764.
77. Liu C, Kuei C, Sutton S, Chen J, Bonaventure P, Wu J, et al,. (2005). INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem 280: 292-300.
78. 2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280: 33178-33189.
79. Ma L, Pei G, (2007). β-arrestin signaling and regulation of transcription. J Cell Sci 120: 213-218.
80. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R, et al,. (2004). Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19: 544-552.
81. Mookerjee I, Solly NR, Royce SG, Tregear GW, Samuel CS, Tang MLK, (2006). Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease. Endocrinology 147: 754-761.
82. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, et al,. (2009). Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219-1229.
83. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, et al,. (2000). High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408: 860-864.
84. Nguyen BT, Dessauer CW, (2005a). Relaxin stimulates protein kinase C ζ translocation: requirement for cyclic adenosine 3â€,5â€-monophosphate production. Mol Endocrinol 19: 1012-1023.
85. Nguyen BT, Dessauer CW, (2005b). Relaxin stimulates cAMP production in MCF-7 cells upon overexpression of type V adenylyl cyclase. Ann N Y Acad Sci 1041: 296-299.
86. Nguyen BT, Yang L, Sanborn BM, Dessauer CW, (2003). Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3â€,5â€-monophosphate by relaxin. Mol Endocrinol 17: 1075-1084.
87. Nie J, Lewis DL, (2001). Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J Neurosci 21: 8758-8764.
88. Nijmeijer S, Leurs R, Smit MJ, Vischer HF, (2010). The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem 285: 29632-29641.
89. Nistri S, Bani D, (2003). Relaxin receptors and nitric oxide synthases: search for the missing link. Reprod Biol Endocrinol 1: 5-6.
90. Novak J, Parry LJ, Matthews JE, Kerchner LJ, Indovina K, Hanley-Yanez K, et al,. (2006). Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J 20: 2352-2362.
91. Orencole SF, Dinarello CA, (1989). Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. Cytokine 1: 14-22.
92. Osa T, Inoue H, Okabe K, (1991). Effects of porcine relaxin on contraction, membrane response and cyclic AMP content in rat myometrium in comparison with the effects of isoprenaline and forskolin. Br J Pharmacol 104: 950-960.
93. Palejwala S, Stein D, Wojtczuk A, Weiss G, Goldsmith LT, (1998). Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts. Endocrinology 139: 1208-1212.
94. Palejwala S, Stein DE, Weiss G, Monia BP, Tortoriello D, Goldsmith LT, (2001). Relaxin positively regulates metrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signalling pathway. Endocrinology 142: 3405-3413.
95. Palejwala S, Tseng L, Wojtczuk A, Weiss G, Goldsmith LT, (2002). Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol Reprod 66: 1743-1748.
96. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, et al,. (1993). Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651.
97. Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, et al,. (1997). Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82: 2695-2701.
98. Parsell DA, Mak JY, Amento EP, Unemori EN, (1996). Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1. J Biol Chem 271: 27936-27941.
99. Pidoux G, Taskén K, (2010). Specificity and spatial dynamics of protein kinase A signalling organised by A-kinase-anchoring proteins. J Mol Endocrinol 44: 271-284.
100. to via PKA-dependent phosphorylation. Am J Physiol 272: H1791-H1797.
101. Piedras-Rentería ES, Sherwood OD, Best PM, (1997b). Effects of relaxin on rat atrial myocytes. II. Increased calcium influx derived from action potential prolongation. Am J Physiol 272: H1798-H1803.
102. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
103. Rau T, Nose M, Remmers U, Weil J, Wiessmüller A, Davia K, et al,. (2003). Overexpression of wild-type Gαi2 suppresses β-adrenergic signalling in cardiac myocytes. FASEB J 17: 523-525.
104. Rondou P, Skieterska K, Packeu A, Lintermans B, Vanhoenacker P, Vauquelin G, et al,. (2010). KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target the receptor for degradation. Cell Signal 22: 900-913.
105. Sadana R, Dessauer CW, (2009). Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17: 5-22.
106. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, et al,. (2004). Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
107. Samuel CS, Royce SG, Chen B, Cao H, Gossen JA, Tregear GW, et al,. (2009). Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease. Endocrinology 150: 1495-1502.
108. Sanborn BM, Kuo HS, Weisbrodt NW, Sherwood OD, (1980). The interaction of relaxin with the rat uterus. I. Effect on cyclic nucleotide levels and spontaneous contractile activity. Endocrinology 106: 1210-1215.
109. Sánchez-Blázquez P, Garzõn J, (1995). αN-acetyl-β-endorphin-(1-31) disrupts the diminishing effect of mastoparan on opioid- and clonidine-evoked supraspinal antinociception in mice. J Pharmacol Exp Ther 273: 787-792.
110. Scott DJ, Layfield S, Yan Y, Sudo S, Hsueh AJW, Tregear GW, et al,. (2006). Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem 281: 34942-34954.
111. Seifert R, Wenzel-Seifert K, (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366: 381-416.
112. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr, (1993). A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365: 652-654.
113. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al,. (2006). β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem 281: 1261-1273.
114. Sherwood OD, (2004). Relaxin's physiological roles and other diverse actions. Endocr Rev 25: 205-234.
115. Shirota K, Tateishi K, Koji T, Hishikawa Y, Hachisuga T, Kuroki M, et al,. (2005). Early human preantral follicles have relaxin and relaxin receptor (LGR7), and relaxin promotes their development. J Clin Endocrinol Metab 90: 516-521.
116. Shpakov AO, Gur'yanov IA, Kuznetsova LA, Plesneva SA, Shpakova EA, Vlasov GP, et al,. (2007). Studies of the molecular mechanisms of action of relaxin on the adenylyl cyclase signaling system using synthetic peptides derived from the LGR7 relaxin receptor. Neurosci Behav Physiol 37: 705-714.
117. Skroblin P, Grossmann S, Schäfer G, Rosenthal W, Klussmann E, (2010). Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol 283: 235-330.
118. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, et al,. (2007). Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47: 53-87.
119. Spooren A, Rondou P, Debowska K, Lintermans B, Vermeulen L, Samyn B, et al,. (2010). Resistance of the dopamine D4 receptor to agonist-induced internalization and degradation. Cell Signal 22: 600-609.
120. Stewart DR, Celniker AC, Taylor CAJ, Cragun JR, Overstreet JW, Lasley BL, (1990). Relaxin in the peri-implantation period. J Clin Endocrinol Metab 70: 1771-1773.
121. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate RA, et al,. (2003). H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem 278: 7855-7862.
122. Summers RJ, Tan YY, Kakouris H, Eddie LW, (1995). Cardiac actions of relaxin. In:, Maclennan AH, Tregear GW, Bryant-Greenwood GD, (eds). Progress in Relaxin Research. Global Publications Services: Singapore, pp. 487-498.
123. Summers RJ, Bathgate RAD, Ivell R, Sanborn BM, Sherwood OD, (2010). Relaxin family peptide receptors. Last modified on 2010-07-01. Accessed on 2011-01-02. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ FamilyMenuForward?familyId=60
124. Svendsen AM, Vrecl M, Ellis TM, Heding A, Kristensen JB, Wade JD, et al,. (2008a). Cooperative binding of insulin-like peptide 3 to a dimeric relaxin family peptide receptor 2. Endocrinology 149: 1113-1120.
125. Svendsen AM, Zalesko A, Konig J, Vrecl M, Heding A, Kristensen JB, et al,. (2008b). Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. Mol Cell Endocrinol 296: 10-17.
126. Tabanelli S, Tang B, Gurpide E, (1992). In vitro decidualization of human endometrial stromal cells. J Steroid Biochem Mol Biol 42: 337-344.
127. Tan YY, Wade JD, Tregear GW, Summers RJ, (1998). Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues. Br J Pharmacol 123: 762-770.
128. Tang B, Guller S, Gurpide E, (1993). Cyclic adenosine 3â€,5â€-monophosphate induces prolactin expression in stromal cells isolated from human proliferative endometrium. Endocrinology 133: 2197-2203.
129. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al,. (2009). Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373: 1429-1439.
130. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M, (2010). Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 7: 75-82.
131. Telgmann R, Gellersen B, (1998). Marker genes of decidualisation: activation of the decidual prolactin gene. Hum Reprod Update 4: 472-479.
132. Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, et al,. (2009). The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation. PLoS ONE 4: e8383.
133. Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, et al,. (2006). Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66: 1698-1709.
134. Tobin AB, Butcher AJ, Kong KC, (2008). Location, location, location. site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 29: 413-420.
135. Tschische P, Moser E, Thompson D, Vischer HF, Parzmair GP, Pommer V, et al,. (2010). The G-protein coupled receptor associated sorting protein GASP-1 regulates the signalling and trafficking of the viral chemokine receptor US28. Traffic 11: 660-674.
136. Ueda H, Inoue M, Yoshida A, Mizuno K, Yamamoto H, Maruo J, et al,. (2001). Metabotropic neurosteroid/sigma-receptor involved in stimulation of nociceptor endings of mice. J Pharmacol Exp Ther 298: 703-710.
137. Unemori EN, Amento EP, (1990). Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 265: 10681-10685.
138. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, et al,. (1996). Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98: 2739-2745.
139. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J, et al,. (1999). Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod 14: 800-806.
140. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, et al,. (2000). Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 8: 361-370.
141. Vinall RL, Tepper CG, Shi X-B, Xue LA, Gandour-Edwards R, de Vere White RW, (2006). The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25: 2082-2093.
142. Ward DG, Thomas GR, Cronin MJ, (1992). Relaxin increases rat heart rate by a direct action on the cardiac atrium. Biochem Biophys Res Commun 186: 999-1005.
143. 3 antagonists. J Pharmacol Exp Ther 299: 908-914.
144. 2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87: 965-1010.
145. 2-adrenoceptor and prostanoid receptor cAMP signalling. J Biol Chem 282: 34235-34249.
146. 2+- dependent cAMP synthesis in pancreatic and neuronal systems. J Biol Chem 285: 20328-20342.
147. Wong W, Scott JD, (2004). AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5: 959-970.
148. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al,. (2007). Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 104: 12011-12016.
149. Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ, (2010). Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 55: 1260-1266.
150. Ying SY, Becker A, Baird A, Ling N, Ueno N, Esch F, et al,. (1986). Type β transforming growth factor (TGF-β) is a potent stimulator of the basal secretion of follicle stimulating hormone (FSH) in a pituitary monolayer system. Biochem Biophys Res Commun 135: 950-956.
151. Zhang Q, Liu S-H, Erikson M, Lewis M, Unemori E, (2002). Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J Cell Biochem 85: 536-544.